B Perez, R Aljumaily, T U Marron, M R Shafique, H Burris, W T Iams, S J Chmura, J J Luke, W Edenfield, D Sohal, X Liao, C Boesler, A Machl, J Seebeck, A Becker, B Guenther, A Rodriguez-Gutierrez, S J Antonia
INTRODUCTION: We report results from a phase I, three-part, dose-escalation study of peposertib, a DNA-dependent protein kinase inhibitor, in combination with avelumab, an immune checkpoint inhibitor, with or without radiotherapy in patients with advanced solid tumors. MATERIALS AND METHODS: Peposertib 100-400 mg twice daily (b.i.d.) or 100-250 mg once daily (q.d.) was administered in combination with avelumab 800 mg every 2 weeks in Part A or avelumab plus radiotherapy (3 Gy/fraction × 10 days) in Part B...
February 5, 2024: ESMO Open